Sergio Wittlin

Dr. Sergio Wittlin


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in ACS Infectious Diseases
Verified
Journal Article
Open access
WNWilliam Nguyen
William Nguyen
MDMadeline G. Dans
Madeline G. Dans
ICIain Currie
Iain Currie
JAJon Kyle Awalt
Jon Kyle Awalt
BBBrodie L. Bailey
Brodie L. Bailey
Brad E. SleebsBrad E. Sleebs
Brad E. Sleebs
The development of new antimalarials is required because of the threat of resistance to current antimalarial therapies. To discover new antimalarial chemotypes, we screened the Janssen Jumpstarter library against the P. falciparum asexual parasite and identified the 7-N-substituted-3-oxadiazole quinolone hit class. We established the structure-activity relationship and optimized the antimalarial potency. The optimized analog WJM228 (17) showed robust metabolic stability in vitro, although the aqueous solubility was limited. Forward genetic resistance studies uncovered that WJM228 targets the Qo site of cytochrome b (cyt b), an important component of the mitochondrial electron transport chain (ETC) that is essential for pyrimidine biosynthesis and an established antimalarial target. Profiling against drug-resistant parasites confirmed that WJM228 confers resistance to the Qo site but not Qi site mutations, and in a biosensor assay, it was shown to impact the ETC via inhibition of cyt b. Consistent with other cyt b targeted antimalarials, WJM228 prevented pre-erythrocytic parasite and male gamete development and reduced asexual parasitemia in a P. berghei mouse model of malaria. Correcting the limited aqueous solubility and the high susceptibility to cyt b Qo site resistant parasites found in the clinic will be major obstacles in the future development of the 3-oxadiazole quinolone antimalarial class.

25 June 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
GDGodwin Akpeko Dziwornu
Godwin Akpeko Dziwornu
DSDonald Seanego
Donald Seanego
SFStephen Fienberg
Stephen Fienberg
MCMonica Clements
Monica Clements
JFJasmin Ferreira
Jasmin Ferreira
KCKelly Chibale
Kelly Chibale
Structure-activity relationship studies of 2,8-disubstituted-1,5-naphthyridines, previously reported as potent inhibitors of Plasmodium falciparum (Pf) phosphatidylinositol-4-kinase β (PI4K), identified 1,5-naphthyridines with basic groups at 8-position, which retained Plasmodium PI4K inhibitory activity but switched primary mode of action to the host hemoglobin degradation pathway through inhibition of hemozoin formation. These compounds showed minimal off-target inhibitory activity against the human phosphoinositide kinases and MINK1 and MAP4K kinases, which were associated with the teratogenicity and testicular toxicity observed in rats for the PfPI4K inhibitor clinical candidate MMV390048. A representative compound from the series retained activity against field isolates and lab-raised drug-resistant strains of Pf. It was efficacious in the humanized NSG mouse malaria infection model at a single oral dose of 32 mg/kg. This compound was nonteratogenic in the zebrafish embryo model of teratogenicity and has a low predicted human dose, indicating that this series has the potential to deliver a preclinical candidate for malaria.

23 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AWAnnabelle Walz
Annabelle Walz
MDMaëlle Duffey
Maëlle Duffey
GAGhaith Aljayyoussi
Ghaith Aljayyoussi
SSSibylle Sax
Sibylle Sax
DLDidier Leroy
Didier Leroy
SWSergio Wittlin
Sergio Wittlin
With artemisinin-resistant Plasmodium falciparum parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and a fast rate of parasite killing or clearance. To determine these parameters, it is essential to discriminate viable from nonviable parasites, which is complicated by the fact that viable parasites can be metabolically inactive, whilst dying parasites can still be metabolically active and morphologically unaffected. Standard growth inhibition assays, read out via microscopy or [3H] hypoxanthine incorporation, cannot reliably discriminate between viable and nonviable parasites. Conversely, the in vitro parasite reduction ratio (PRR) assay is able to measure viable parasites with high sensitivity. It provides valuable pharmacodynamic parameters, such as PRR, 99.9% parasite clearance time (PCT99.9%) and lag phase. Here we report the development of the PRR assay version 2 (V2), which comes with a shorter assay duration, optimized quality controls and an objective, automated analysis pipeline that systematically estimates PRR, PCT99.9% and lag time and returns meaningful secondary parameters such as the maximal killing rate of a drug (Emax) at the assayed concentration. These parameters can be fed directly into pharmacokinetic/pharmacodynamic models, hence aiding and standardizing lead selection, optimization, and dose prediction.

18 December 2019 in Malaria Journal
Verified
Journal Article
Open access
PDF file
AWAnnabelle Walz
Annabelle Walz
DLDidier Leroy
Didier Leroy
NANicole Andenmatten
Nicole Andenmatten
PMPascal Mäser
Pascal Mäser
SWSergio Wittlin
Sergio Wittlin
Background: Drug efficacy against kelch 13 mutant malaria parasites can be determined in vitro with the ring-stage survival assay (RSA). The conventional assay protocol reflects the exposure profile of dihydroartemisinin. Methods: Taking into account that other anti-malarial peroxides, such as the synthetic ozonides OZ439 (artefenomel) and OZ609, have different pharmacokinetics, the RSA was adjusted to the concentration–time profile of these ozonides in humans and a novel, semi-automated readout was introduced. Results: When tested at clinically relevant parameters, it was shown that OZ439 and OZ609 are active against the Plasmodium falciparum clinical isolate Cam3.IR539T. Conclusion: If the in vitro RSA does indeed predict the potency of compounds against parasites with increased tolerance to artemisinin and its derivatives, then the herein presented data suggest that following drug-pulses of at least 48 h, OZ439 and OZ609 will be highly potent against kelch 13 mutant isolates, such as P. falciparum Cam3.IR539T.

17 August 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
HDHeledd Davies
Heledd Davies
BBBärbel Bergmann
Bärbel Bergmann
PWPhilipp Walloch
Philipp Walloch
CNCornelius Nerlich
Cornelius Nerlich
CHChristian Hansen
Christian Hansen
EBEric Beitz
Eric Beitz
Malaria parasites in the blood stage express a single transmembrane transport protein for the release of the glycolytic end product l -lactate/H + from the cell. This transporter is a member of the strictly microbial formate-nitrite transporter (FNT) family and a novel putative drug target.

7 January 2011 in Nature Medicine
Verified
Journal Article
Open access
PDF file
WBWerner Baschong
Werner Baschong
SWSergio Wittlin
Sergio Wittlin
KIKirstine A Inglis
Kirstine A Inglis
AFAlan Fairlamb
Alan Fairlamb
SCSimon Croft
Simon Croft
RBReto Brun
Reto Brun
Triclosan is minimally effective in rodent malaria models